Reproducibility of Quantitative 18F-3'-deoxy-3'-fluorothymidine Measurements Using Positron Emission Tomography

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2008 Oct 22

PMID 18931838

Citations 34

Authors

Adrianus J de Langen

Bianca Klabbers

Mark Lubberink

Ronald Boellaard

Marieke D Spreeuwenberg

Ben J Slotman

Remco de Bree

Egbert F Smit

Otto S Hoekstra

Adriaan A Lammertsma

Affiliations

Soon will be listed here.

Abstract

Purpose: Positron emission tomography (PET) using (18)F-3'-deoxy-3'-fluorothymidine ([(18)F]FLT) allows noninvasive monitoring of tumour proliferation. For serial imaging in individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative [(18)F]FLT measurements.

Methods: Nine patients with non-small-cell lung cancer (NSCLC) and six with head-and-neck cancer (HNC) underwent [(18)F]FLT PET twice within 7 days prior to therapy. The maximum pixel value (SUV(max)) and a threshold defined volume (SUV(41%)) were defined for all delineated lesions. The plasma to tumour transfer constant (K(i)) was estimated using both Patlak graphical analysis and nonlinear regression (NLR). NLR was also used to estimate k(3), which, at least in theory, selectively reflects thymidine kinase 1 activity. The level of agreement between test and retest values was assessed using the intraclass correlation coefficient (ICC) and Bland-Altman analysis.

Results: All primary tumours and >90% of clinically suspected locoregional metastases could be delineated. In total, 24 lesions were defined. NLR-derived K(i), Patlak-derived K(i), SUV(41%) and SUV(max) showed excellent reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and SDs of 16%, 12%, 7% and 11%, respectively. Reproducibility was poor for k(3) with an ICC of 0.43 and SD of 38%.

Conclusion: Quantitative [(18)F]FLT measurements are reproducible in both NSCLC and HNC patients. When monitoring response in individual patients, changes of more than 15% in SUV(41%), 20-25% in SUV(max) and Patlak-derived K(i), and 32% in NLR3k-derived K(i) are likely to represent treatment effects.

Citing Articles

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show F-Fluorothymidine "Flare" on Positron Emission Tomography.

Aravind P, Popat S, Barwick T, Soneji N, Lythgoe M, Sreter K Cancers (Basel). 2023; 15(14).

PMID: 37509378 PMC: 10377924. DOI: 10.3390/cancers15143718.

Role of 3'-Deoxy-3'-[F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.

Szyszko T, Dunn J, Phillips M, Bomalaski J, Sheaff M, Ellis S JTO Clin Res Rep. 2022; 3(9):100382.

PMID: 36082278 PMC: 9445378. DOI: 10.1016/j.jtocrr.2022.100382.

Dynamic whole-body PET imaging: principles, potentials and applications.

Rahmim A, Lodge M, Karakatsanis N, Panin V, Zhou Y, McMillan A Eur J Nucl Med Mol Imaging. 2018; 46(2):501-518.

PMID: 30269154 DOI: 10.1007/s00259-018-4153-6.

Repeatability of quantitative F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis.

Kramer G, Liu Y, de Langen A, Jansma E, Trigonis I, Asselin M Eur J Nucl Med Mol Imaging. 2018; 45(6):951-961.

PMID: 29362858 PMC: 5915500. DOI: 10.1007/s00259-017-3923-x.

Repeatability of F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

Lodge M, Holdhoff M, Leal J, Bag A, Nabors L, Mintz A J Nucl Med. 2016; 58(3):393-398.

PMID: 27688473 PMC: 5331936. DOI: 10.2967/jnumed.116.178434.

References

Boellaard R, van Lingen A, van Balen S, Lammertsma A . Optimization of attenuation correction for positron emission tomography studies of thorax and pelvis using count-based transmission scans. Phys Med Biol. 2004; 49(4):N31-8. DOI: 10.1088/0031-9155/49/4/n01. View

Hoekstra C, Hoekstra O, Lammertsma A . On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies. Eur J Nucl Med. 1999; 26(11):1489-92. DOI: 10.1007/s002590050484. View

Boellaard R, van Lingen A, Lammertsma A . Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med. 2001; 42(5):808-17. View

Dimitrakopoulou-Strauss A, Strauss L . The role of 18F-FLT in cancer imaging: does it really reflect proliferation?. Eur J Nucl Med Mol Imaging. 2008; 35(3):523-6. DOI: 10.1007/s00259-007-0679-8. View

Been L, Elsinga P, de Vries J, Cobben D, Jager P, Hoekstra H . Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol. 2005; 32(1):39-43. DOI: 10.1016/j.ejso.2005.09.011. View

Buck A, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D . Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007; 34(11):1775-82. DOI: 10.1007/s00259-007-0452-z. View

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

PATLAK C, Blasberg R, Fenstermacher J . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3(1):1-7. DOI: 10.1038/jcbfm.1983.1. View

Hoekstra C, Hoekstra O, Lammertsma A . On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies. Eur J Nucl Med. 2000; 27(10):1579. DOI: 10.1007/s002590000327. View

10.

Cobben D, Elsinga P, Hoekstra H, Suurmeijer A, Vaalburg W, Maas B . Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. J Nucl Med. 2004; 45(10):1677-82. View

11.

Hoekstra C, Paglianiti I, Hoekstra O, Smit E, Postmus P, Teule G . Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000; 27(6):731-43. DOI: 10.1007/s002590050570. View

12.

Buck A, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G . Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003; 44(9):1426-31. View

13.

Boellaard R, Oyen W, Hoekstra C, Hoekstra O, Visser E, Willemsen A . The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008; 35(12):2320-33. DOI: 10.1007/s00259-008-0874-2. View

14.

Kenny L, Coombes R, Vigushin D, Al-Nahhas A, Shousha S, Aboagye E . Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007; 34(9):1339-47. DOI: 10.1007/s00259-007-0379-4. View

15.

Boellaard R, van Lingen A, van Balen S, Hoving B, Lammertsma A . Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med. 2001; 28(1):81-9. DOI: 10.1007/s002590000405. View

16.

Muzi M, Spence A, OSullivan F, Mankoff D, Wells J, Grierson J . Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006; 47(10):1612-21. View

17.

Barthel H, Cleij M, Collingridge D, Hutchinson O, Osman S, He Q . 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003; 63(13):3791-8. View

18.

Dittmann H, Dohmen B, Paulsen F, Eichhorn K, Eschmann S, Horger M . [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003; 30(10):1407-12. DOI: 10.1007/s00259-003-1257-3. View

19.

Erdi Y, Mawlawi O, Larson S, Imbriaco M, Yeung H, Finn R . Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997; 80(12 Suppl):2505-9. DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2505::aid-cncr24>3.3.co;2-b. View

20.

Apisarnthanarax S, Alauddin M, Mourtada F, Ariga H, Raju U, Mawlawi O . Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006; 12(15):4590-7. DOI: 10.1158/1078-0432.CCR-05-2720. View